MelanomaKIT Clinical Trials
KIT mutations and amplifications occur in approximately 10–15% of mucosal and acral melanoma subtypes — underrepresented in cutaneous melanoma trials — and predict response to KIT inhibitors. Imatinib and nilotinib have demonstrated responses in KIT-mutant mucosal/acral melanoma. Trials investigate KIT inhibitor combinations with immunotherapy and novel multi-kinase inhibitors in KIT-altered non-cutaneous melanoma.
Top recruiting KIT Melanoma trials
Ranked by phase and US site count. See all 4 trials matched to your profile →
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
University of California, San Francisco
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
M.D. Anderson Cancer Center
Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
Fudan University
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
Browse other molecular targets with active Melanoma trials.